Lassa fever treatment options
Pro Research Analysisby 
Searched over 200M research papers
Current Lassa Fever Treatment Options: Ribavirin and Supportive Care
The main treatment for Lassa fever is supportive care, which includes managing symptoms and complications as they arise. Ribavirin, an antiviral medication, is the most commonly used drug for treating acute Lassa fever, especially when started early in the course of the disease. However, the evidence supporting ribavirin’s effectiveness is limited and mostly based on a single clinical trial with a high risk of bias. Some studies suggest ribavirin may reduce mortality in patients with severe disease (elevated AST), but it could potentially increase the risk of death in patients with milder forms of Lassa fever, raising concerns about its universal use and highlighting the need for urgent reassessment of its role in treatment 45910.
Investigational and Emerging Therapies for Lassa Fever
Favipiravir and Combination Therapy
Favipiravir, another antiviral, has shown promise in animal studies and has been used in combination with ribavirin in a few human cases, where both patients survived. However, these cases also showed prolonged viral RNA in blood and semen, suggesting the need for further research on its effectiveness and implications for transmission 128.
Monoclonal Antibody Therapies
Recent advances have led to the development of monoclonal antibody (MAb) therapies targeting the Lassa virus glycoprotein. A cocktail of three human MAbs, known as Arevirumab-3, demonstrated 100% survival in animal models even when administered at advanced stages of disease. These antibody therapies are considered promising and may become key treatment options pending further clinical trials in endemic regions 12310.
Other Experimental and Repurposed Drugs
Several other drugs are under investigation for Lassa fever treatment, including:
- LHF-535, a small-molecule antiviral, has shown good safety and pharmacokinetics in early human trials, with exposures predicted to suppress viral replication 17.
- Other experimental agents such as taribavirin, losmapimod, adamantyl diphenyl piperazine 3.3, Arbidol (umifenovir), and decanoyl-RRLL-chloromethyl ketone (dec-RRLL-CMK) are being explored, but their efficacy and safety in humans remain to be established .
Convalescent Plasma and Other Approaches
Convalescent plasma, derived from recovered Lassa fever patients, has not shown sufficient evidence of benefit and is not currently recommended as a standard treatment 14.
Challenges and Future Directions in Lassa Fever Treatment
There are currently no approved vaccines or highly effective therapeutics for Lassa fever. The genetic diversity of the Lassa virus and its ability to evade the immune system complicate the development of effective treatments and vaccines. Ongoing research is focused on drug repurposing, novel antiviral agents, and targeting viral proteins such as the nucleoprotein (NP) for new therapies 16.
Conclusion
Lassa fever treatment options remain limited, with ribavirin as the mainstay despite questions about its efficacy and safety. Promising new therapies, including favipiravir, monoclonal antibodies, and novel antivirals like LHF-535, are in development and may improve outcomes in the future. Until more effective treatments and vaccines are available, early diagnosis, supportive care, and preventive measures are critical in managing Lassa fever, especially in endemic regions 12345678+2 MORE.
Sources and full results
Most relevant research papers on this topic